CRSP: financial statements from SEC — TradeAlmanac

CRSP

CRISPR Therapeutics AG: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	4m	37m
Research and development	285m	310m
Selling, general and administrative	74m	73m
Operating expenses	668m	504m
Operating income	−665m	−467m
Pre-tax income	−578m	−363m
Income tax	4m	4m
Net income	−582m	−366m
Earnings per share	−6.47	−4.34
Earnings per share, diluted	−6.47	−4.34
Weighted average shares	90m	84m
Weighted average shares, diluted	90m	84m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	423m	348m	286m	194m	235m	298m	226m	484m
Short-term investments	2.02bn	1.63bn

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	−345m	−143m
Depreciation and amortisation	19m	19m
Share-based compensation	72m	87m
Capital expenditure	914,000	2m
Investing cash flow	−32m	−280m
Financing cash flow	426m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)